Small Cell Lung Cancer
The Breakthrough Therapy Designation is based on results from the ES-SCLC cohort in the global phase 2 TROPiCS-03 study.
The phase 2 expansion portion of the trial will enroll approximately 50 patients at 10 to 15 sites in the United States.
Certain groups continue to experience higher rates of lung cancer mortality related to chronic lower respiratory diseases.
Investigators evaluated the efficacy of durvalumab in the randomized, double-blind, placebo-controlled ADRIATIC trial.
Researchers evaluated the immunogenicity and safety of the COVID-19 vaccine in patients with lung cancer.
The recent report shows that the "breadth of tobacco-caused disparities continues to persist and expand."
Advertisement
Expert Interviews on Lung Cancer
Advertisement
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.